Skip to main content
Melanie Calvert on Muck Rack

Melanie Calvert

As seen in: Nature, Memory Studies, PLOS Medicine, BMJ Oncology, BMJ Open, MDPI, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, The Lancet, American Journal of Kidney Diseases
Professor Outcomes Methodology, Director @CPROR_UoB & BHP Centre Regulatory Science & Innovation #NIHR Senior Investigator Passionate #PROs #CRSI #spiritAI #PPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Melanie

Contact Melanie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Optimising patient centred drug development to realise impact

|
By Melanie Calvert, Paul Kamudoni, Christina Yap, Claire F Snyder, Roger Wilson, Olalekan Lee Aiyegbusi
| Nature Verified
Patient-reported outcomes can provide valuable evidence on the efficacy and tolerability of treatments throughout the drug development pipeline supporting regulatory decision-making, reimbursement and patient-centred care. Use of international guidelines and tools can optimise assessment and data quality and maximise impact.
Open in Who Shared Issue with article?

Symptoms, side effects, quality of life and financial toxicity matter to patients with cancer, we need to do a better job of capturing and reporting these concepts in trials and clinical care

|
By Melanie Calvert, Roger Wilson, John Devin Peipert
| BMJ Oncology Verified
For those experiencing a cancer diagnosis, survival and disease progression are at the forefront of minds. Alongside this, patients want to understand disease symptoms, potential side effects of therapies and impacts on their quality of life and ability to take part in social activities, education and work.
Open in Who Shared Issue with article?

The risk of Long Covid symptoms: a systematic review and meta-analysis of controlled studies - Nature Communications

|
By Lauren O’Mahoney, Ash Routen, Abdullah Almaqhawi, Daniel Ayoubkhani, Amitava Banerjee, Melanie Calvert, Shabana Cassambai, Mark Funnell, Rachael Evans, Shavez Jeffers, Roz Shafran, Terence Stephenson, Jonathan A. Sterne, Helen Ward, Tom Ward
| Nature Verified
Abstract The global evidence on the risk of symptoms of Long Covid in general populations infected with SARS-CoV-2 compared to uninfected comparator/control populations remains unknown. We conducted a systematic literature search using multiple electronic databases from January 1, 2022, to August 1, 2024. Included studies had ≥100 people with confirmed or self-reported COVID-19 at ≥28 days following infection onset, and an uninfected comparator/control group.
Open in Who Shared Issue with article?
See all 40 licensed articles (46 Total)